Talk:Enzalutamide

This is the talk page for discussing improvements to the Enzalutamide article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Enzalutamide.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Chemicals Low‑importance

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
Low	This article has been rated as Low-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Section

Needs a vector (SVG) version of chemical. —Preceding unsigned comment added by 140.226.190.83 (talk) 16:06, 7 September 2010 (UTC)[reply]

Phase III trials

Here are the 2 journal publications of the phase III trial, which should go in the entry. The NEJM article is free online.

http://www.ncbi.nlm.nih.gov/pubmed/22894553

http://www.ncbi.nlm.nih.gov/pubmed/23300275

--Nbauman (talk) 11:22, 18 October 2013 (UTC)[reply]

Off-label Hairloss treatment

It's being used as a topical hair loss treatment by Alopecia Androgenetica sufferers...

https://www.hairlosstalk.com/interact/threads/mdv3100-enzalutamide-superstrong-antiandrogen-topical.105093/

https://www.alopezie.de/fud/index.php/t/30791/

--78.51.19.35 (talk) 00:40, 30 November 2017 (UTC)[reply]

Priority Review for combination with ADT for some prostate cancer

Could mention Priority Review and PROSPER trial [1] in a Clinical Trials section or at least in History ? Summarise : "The sNDA is based on data from the phase 3 PROSPER trial in which the combination of Xtandi and androgen deprivation therapy (ADT) reduced the risk of metastases or death by 71 percent compared with ADT alone for patients with nonmetastatic CRPC. ... the median metastasis-free survival (MFS) was 36.6 months with Xtandi plus ADT versus 14.7 months with ADT alone." ... "There was a 93 percent reduction in the risk of PSA progression in the Xtandi arm compared with ADT alone. The median time to PSA progression in the Xtandi group was 37.2 months compared with 3.9 months for ADT alone. The time to next antineoplastic therapy was extended by a median of 21.9 months with Xtandi versus ADT alone. Men enrolled in the Xtandi arm required a new therapy after a median of 39.6 months compared with 17.7 months in the placebo group, representing a 79 percent reduction in the risk of requiring a new therapy." - Rod57 (talk) 17:29, 23 March 2018 (UTC)[reply]